相关实验视频

Updated: Jun 4, 2025

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

随机临床试验中的终点选择对高缩性心肌病的随机临床试验

Alberto Aimo¹, Iacopo Olivotto², Giancarlo Todiere³

¹Health Sciences Interdisciplinary Center, Scuola Superiore Sant'Anna, Pisa, Italy; Cardiology Division, Fondazione Toscana Gabriele Monasterio, Pisa, Italy.

JACC. Heart failure

|December 21, 2024

概括

设计高伤心肌病 (HCM) 的临床试验是复杂的,因为它的稀有性和多样化的呈现. 未来的试验将整合遗传见解和先进技术,以改善患者的治疗结果.

科学领域:

心脏病学心脏病学
遗传学遗传学是一个
临床试验设计临床试验设计

背景情况:

超性心肌病 (HCM) 研究面临的挑战是由于稀有性,低事件率和多样化的呈现.
萨尔科默蛋白基因 (例如,MYH7,MYBPC3) 的遗传变异有助于HCM的多样化表型和治疗反应.

研究的目的:

探索设计超性心肌病随机临床试验 (RCT) 的复杂性和进步.
确定临床上有意义的终点,并讨论将遗传见解和新技术纳入HCM研究的整合.

主要方法:

审查HCM临床试验设计中的挑战,包括终点选择和统计考虑.
讨论新兴疗法 (如基因疗法) 以及它们对试验设计的影响.
分析当前和未来的终点策略,包括患者报告的结果和硬临床终点.

主要成果:

对HCM的RCT因罕见性,低事件率和表型多样性而复杂.
临床上有意义的终点至关重要,但由于测试-重新测试可变性等因素,很难确定.
遗传变异性需要个性化试验方法,基因疗法显示出希望.

结论:

未来的HCMRCT需要整合遗传洞察力和先进技术以改进设计.
正在考虑一系列更广泛的终点,包括患者报告的结果和严重的临床事件.
个性化的方法和强大的终点选择是提高HCM试验患者结果的关键.

关键词:

在HCM中,HCM是指HCM.终点终点终点是一个终点.过度缩性心肌病变性心脏病.研究设计研究设计试验试验试验试验试验试验试验

更多相关视频

High-Throughput Cardiotoxicity Screening Using Mature Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Monolayers

High-Throughput Cardiotoxicity Screening Using Mature Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Monolayers

Published on: March 24, 2023

Isolation and Functional Characterization of Human Ventricular Cardiomyocytes from Fresh Surgical Samples

Isolation and Functional Characterization of Human Ventricular Cardiomyocytes from Fresh Surgical Samples

Published on: April 21, 2014

相关概念视频

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...